| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of
*
Hematology/Oncology and
Nuclear Medicine, University of Regensburg, Regensburg, Germany
Adoptive T cell therapy has been successfully used for treatment of viral and malignant diseases. However, little is known about the fate and trafficking of transferred Ag-specific T cells. Using the tetramer (TM) technology which allows for detection and quantification of Ag-specific CTL, we assessed the frequency of circulating Melan-A-specific CTL in advanced melanoma patients during adoptive T cell therapy. Melan-A-specific CTL were generated from HLA-A2.1+ patients by in vitro stimulation of CD8+ T cells with dendritic cells pulsed with a mutated HLA-A2-binding Melan-A (ELAGIGILTV) peptide. Eight patients received three infusions of 0.25–11 x 108 Melan-A-specific CTL i.v. at 2-wk intervals along with low-dose IL-2. The transferred T cell product contained a mean of 42.1% Melan-A-TM+ CTL. Before therapy, the frequencies of Melan-A-specific CTL in patients’ circulating CD8+ T cells ranged from 0.01 to 0.07%. Characterization of the TM frequencies before and at different time points after transfer revealed an increase of circulating Melan-A-specific CTL up to 2%, correlating well with the number of transferred CTL. An elevated frequency of TM+ T cells was demonstrated up to 14 days after transfer, suggesting long-term survival and/or proliferation of transferred CTL. Combining TM analysis with a flow cytometry-based cytokine secretion assay, unimpaired production of IFN-
was demonstrated in vivo for at least 24 h after transfer. Indium-111 labeling of Melan-A-specific CTL demonstrated localization of transferred CTL to metastatic sites as early as 48 h after injection. Overall, the results suggest that in vitro-generated Melan-A-specific CTL survive intact in vivo for several weeks and localize preferentially to tumor.
This article has been cited by other articles:
|
|
 |
|
  G. Bricard, V. Cesson, E. Devevre, H. Bouzourene, C. Barbey, N. Rufer, J. S. Im, P. M. Alves, O. Martinet, N. Halkic, et al. Enrichment of Human CD4+ V{alpha}24/V{beta}11 Invariant NKT Cells in Intrahepatic Malignant Tumors J. Immunol., April 15, 2009; 182(8): 5140 - 5151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yee Adoptive T Cell Therapy: Stratagems and Spoils ASCO Educational Book, January 1, 2009; 2009(1): 511 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mackensen Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy ASCO Educational Book, January 1, 2009; 2009(1): 521 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Godet, A. Moreau-Aubry, Y. Guilloux, V. Vignard, A. Khammari, B. Dreno, F. Jotereau, and N. Labarriere MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency J. Exp. Med., October 27, 2008; 205(11): 2673 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hambach, M. Vermeij, A. Buser, Z. Aghai, T. van der Kwast, and E. Goulmy Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors Blood, September 1, 2008; 112(5): 1844 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weishaupt, K. N. Munoz, E. Buzney, T. S. Kupper, and R. C. Fuhlbrigge T-Cell Distribution and Adhesion Receptor Expression in Metastatic Melanoma Clin. Cancer Res., May 1, 2007; 13(9): 2549 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger, E. Gottfried, S. Schwarz, G. Rothe, S. Hoves, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood, May 1, 2007; 109(9): 3812 - 3819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fischer, S. Voelkl, J. Berger, R. Andreesen, T. Pomorski, and A. Mackensen Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells Blood, December 15, 2006; 108(13): 4094 - 4101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Walton, M. Gerlinger, O. de la Rosa, N. Nuber, A. Knights, A. Gati, M. Laumer, L. Strauss, C. Exner, N. Schafer, et al. Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients J. Immunol., December 1, 2006; 177(11): 8212 - 8218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma J. Clin. Oncol., November 1, 2006; 24(31): 5060 - 5069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gottfried, L. A. Kunz-Schughart, S. Ebner, W. Mueller-Klieser, S. Hoves, R. Andreesen, A. Mackensen, and M. Kreutz Tumor-derived lactic acid modulates dendritic cell activation and antigen expression Blood, March 1, 2006; 107(5): 2013 - 2021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Vignard, B. Lemercier, A. Lim, M.-C. Pandolfino, Y. Guilloux, A. Khammari, C. Rabu, K. Echasserieau, F. Lang, M.-L. Gougeon, et al. Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells J. Immunol., October 1, 2005; 175(7): 4797 - 4805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupont, J.-B. Latouche, C. Ma, and M. Sadelain Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells Cancer Res., June 15, 2005; 65(12): 5417 - 5427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fischer, S. Voelkl, J. Heymann, G. K. Przybylski, K. Mondal, M. Laumer, L. Kunz-Schughart, C. A. Schmidt, R. Andreesen, and A. Mackensen Isolation and characterization of human antigen-specific TCR{alpha}{beta}+ CD4-CD8- double-negative regulatory T cells Blood, April 1, 2005; 105(7): 2828 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bricard, H. Bouzourene, O. Martinet, D. Rimoldi, N. Halkic, M. Gillet, P. Chaubert, H. R. MacDonald, P. Romero, J.-C. Cerottini, et al. Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma J. Immunol., February 1, 2005; 174(3): 1709 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Meidenbauer, A. Zippelius, M. J. Pittet, M. Laumer, S. Vogl, J. Heymann, M. Rehli, B. Seliger, S. Schwarz, F.-A. L. Gal, et al. High Frequency of Functionally Active Melan-A-Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma Cancer Res., September 1, 2004; 64(17): 6319 - 6326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paczesny, J. Banchereau, K. M. Wittkowski, G. Saracino, J. Fay, and A. K. Palucka Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells J. Exp. Med., June 7, 2004; 199(11): 1503 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses J. Immunol., February 1, 2004; 172(3): 1380 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, J. C. Hylind, and R. W. Dutton Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases Cancer Res., January 1, 2004; 64(1): 406 - 414. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
